QTTB Company Profile and Key Details

NASDAQ : QTTB

Q32 Bio

$15.21

0.06+0.40%

At Close 4:00 PM

$14.59

+0.51+3.62%

After-Market 08:30 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Q32 Bio Inc. (QTTB) stock surged +3.29%, trading at $15.71 on NASDAQ, up from the previous close of $15.21. The stock opened at $15.71, fluctuating between $14.79 and $15.89 in the recent session.

Stock Snapshot

15.21

Prev. Close

200.72M

Market Cap

14.79

Day Low

9.08

P/E Ratio

1.73

EPS (TTM)

N/A

Cash Flow per Share

15.71

Open

12.78M

Number of Shares

15.89

Day High

36.58%

Free Float in %

N/A

Book Value

535.27K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 27, 2026	15.37	16.61	15.11	15.21	527.4K
Jul 24, 2026	15.26	15.59	14.97	15.15	178.8K
Jul 23, 2026	15.00	15.68	14.93	15.38	393.2K
Jul 22, 2026	15.22	15.74	14.98	15.08	609.91K
Jul 21, 2026	14.88	15.43	14.13	15.41	855.19K
Jul 20, 2026	14.68	16.00	14.54	15.04	1.27M
Jul 17, 2026	15.13	15.95	14.75	15.05	1.32M
Jul 16, 2026	15.99	15.99	14.67	15.21	2.34M
Jul 15, 2026	18.25	18.26	15.56	15.70	7.06M
Jul 14, 2026	21.25	23.57	17.50	18.46	3.56M
Jul 13, 2026	18.31	22.50	17.28	21.38	27.73M
Jul 10, 2026	12.38	12.48	10.82	11.21	3.2M
Jul 09, 2026	14.26	14.43	12.31	12.59	264.78K
Jul 08, 2026	13.46	14.42	12.65	14.08	435.94K
Jul 07, 2026	13.48	14.20	12.66	13.62	239.32K
Jul 06, 2026	13.09	13.76	12.73	12.87	247.36K
Jul 02, 2026	12.68	13.30	12.54	13.09	162.68K
Jul 01, 2026	12.87	13.06	12.43	12.60	193.38K
Jun 30, 2026	14.16	14.85	12.31	12.74	539.74K
Jun 29, 2026	13.17	15.02	13.04	14.14	716.7K

Contact Details

Waltham, MA 02451

United States

https://www.q32bio.com 781 999 0232

About Company

Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.

Stock Peers

ARGX

-29.4-3.20%

argenx SE$888.82 REGN

11.16+1.70%

Regeneron Pharmaceuticals, Inc.$667.17 MDGL

6.74+1.24%

Madrigal Pharmaceuticals, Inc.$551.25 UTHR

-0.53-0.10%

United Therapeutics Corporation$527.94 VRTX

1.64+0.34%

Vertex Pharmaceuticals Incorporated$479.00 KRYS

16.63+4.96%

Krystal Biotech, Inc.$351.82 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ONC

BeOne Medicines AG$325.90 PRAX

-9.5-2.92%

Praxis Precision Medicines, Inc.$315.80 LGND

-3.03-1.01%

Ligand Pharmaceuticals Incorporated$297.50

Company Overview

Q32 Bio Inc. (NASDAQ:QTTB) closed at $15.71 USD, gaining $0.50 (3.29%) from the previous close of $15.21. The stock is currently mid-range between its 52-week high and low $1.57 and $23.57. With a market capitalization of about $200.72 million, Q32 Bio Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.27). Key stats such as the average daily volume over the past year has been around 1.50 million shares, volume is running light vs its 52-week average. Headquartered in Waltham, MA, Q32 Bio Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jodie Pope Morrison, the company employs approximately 24 people and listed since March 28, 2018. Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses.

Technical Performance

QTTB has shown sold momentum, gaining 7.97% over the past week and 23.97% over the past quarter, though year-to-date performance is up 18.37%. Short-term trend indicators are bearishly aligned (SMA20 14.16%, SMA50 27.24%, SMA200 86.11%). The stock’s 14-day RSI is 63.58 (firm momentum), while the ATR of 0.39 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -25.27% below its high and over 253.9% above its low. Average 10-day trading volume of 639.15 thousand shares is below the 3-month average of 1.50 million, indicating normal recent market interest.

Valuation Metrics

Q32 Bio Inc. trades at a P/E ratio of 5.79, slightly below the S&P 500 average, with a price-to-sales ratio of 3.69 and a price-to-book ratio of 4.73 trading at moderately above to book value. The P/FCF stands at -7.24, also below market averages.

Dividend & Fair Value

Q32 Bio Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.26. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Q32 Bio Inc. generated EPS of -$3.45 over the past year. Five-year average earnings growth is 31.75%. Wall Street analysts project EPS growth of 15.19% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $66.00 to $13.00. The high target offers 333.93% upside. The low target suggests -14.53% downside. The mean target is $30.33. This offers 99.41% upside. Q32 Bio Inc. earnings surprise history is frequent misses against expectations. The quarter that ended May 05, 2026, missed forecasts by -20.59%. The prior quarter beat by -529.41%. Over the last six quarters, Apple has recorded several small beats. These include -7.2% in March 11, 2025.

Shareholding & Insider Activity

Q32 Bio Inc. has 29.71 million shares outstanding. The public float is 2.60 million shares, elevated short interest at 15.22% of float. This equals 2.26 million shares. The short ratio is 0.99 days. Institutional investors hold 112.25% of the float. Insiders own 4.56%. Xu Diyong holds 625.00 thousand shares, ORBIMED ADVISORS LLC has 625.00 thousand shares and Morrison Jodie Pope has 89.10 thousand shares. Over the past six months, insider transactions show net selling. They sold 16.71 thousand shares across 3 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Q32 Bio has not generated any revenue.
On valuation metrics, Q32 Bio trades at a P/E of 5.79, P/S of 3.69 and P/B of 4.73. The current ratio is 5.36 and quick ratio is 5.36. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -621.79 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.29, supported by a cash flow-to-debt ratio of -2.01.

Price Forecast & Outlook

Our AI price prediction model suggests that Q32 Bio Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 11.7%, with price expected at $16.99 by August 10, 2026, within a range of $15.02 to $18.98 3-Month Outlook: Projected rise of 48.85%, reaching $22.64 by October 23, 2026, with a range of $19.73 to $24.38. 1-Year Outlook: Projected loss of -29.13%, with price at $10.78 by July 27, 2027, within a range of $6.35 to $15.13.

Key Takeaways

Q32 Bio Inc. (NASDAQ:QTTB) shares are up 18.37% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Q32 Bio Inc. trading at a premium to the broader market with a P/E of 5.79. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $28.06, suggesting 84.48% upside. Our AI forecast model points to short-term strength (11.7% over two weeks), a medium-term rise (48.85% over three months), and a longer-term loss (-29.13% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Q32 Bio Inc. (QTTB) stock price?

Q32 Bio Inc. (NASDAQ: QTTB) stock price is $15.71 in the last trading session. During the trading session, QTTB stock reached the peak price of $15.89 while $14.79 was the lowest point it dropped to. The percentage change in QTTB stock occurred in the recent session was 3.29% while the dollar amount for the price change in QTTB stock was $0.50.

QTTB's industry and sector of operation?

The NASDAQ listed QTTB is part of Biotechnology industry that operates in the broader Healthcare sector. Q32 Bio Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of QTTB?

No Data

How QTTB did perform over past 52-week?

QTTB's closing price is 869.41% higher than its 52-week low of $1.57 where as its distance from 52-week high of $23.57 is -35.47%.

How many employees does QTTB have?

Number of QTTB employees currently stands at 24.

Link for QTTB official website?

Official Website of QTTB is: https://www.q32bio.com

How do I contact QTTB?

QTTB could be contacted at phone 781 999 0232 and can also be accessed through its website. QTTB operates from 830 Winter Street, Waltham, MA 02451, United States.

How many shares of QTTB are traded daily?

QTTB stock volume for the day was 535.27K shares. The average number of QTTB shares traded daily for last 3 months was 1.5M.

What is the market cap of QTTB currently?

The market value of QTTB currently stands at $200.72M with its latest stock price at $15.71 and 12.78M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	24
Beta	-0.27
Sales or Revenue	N/A
5Y Sales Change%	-1.166%
Fiscal Year Ends	N/A
Sector	Healthcare
Industry	Biotechnology

QTTB Company Profile and Key Details

Q32 Bio

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Company Overview

Dividend & Fair Value

Shareholding & Insider Activity

Valuation Metrics

Financial & Profitability Overview

Price Forecast & Outlook

Key Takeaways